Hedge Fund Surges 119% on Bullish Valeant Bet

  • Fund led by ex-Farallon Capital Management manager Ding Chun
  • Hedge fund said to have seen quality assets, solid cashflow
Valeant Pharmaceuticals International, Inc. signage displayed on a monitor on the floor of the New York Stock Exchange (NYSE) in New York, U.S., before the opening bell on March 21, 2016.

Photographer: Michael Nagle/Bloomberg

Lock
This article is for subscribers only.

A bullish bet on Valeant Pharmaceuticals International Inc., the drugmaker that spurred losses for Bill Ackman’s investment firm, helped a San Francisco-based hedge fund to a 119 percent gain last year, according to a person familiar with the matter.

ChinaRock Capital Management bet that quality assets, good cash flow and a management incentive plan would help Valeant rebound after an 86 percent plunge in 2016 priced the company below its liquidation value, said the person, who asked not to be identified because the information is private.